Cinnatropin, produced by Cinnagen, a licensed pharmaceutical company based in Iran, fails to meet USP Pharmacopaeia standards for "Dimer Content" (≤ 4% high weight molecular proteins) and is regarded fairly as an unsafe medication that is associated with more severe lethargy (decreased tolerability) and reduced efficacy (decreased potency) than reference quality pharmaceutical preparations (e.g., Novo-Nordisk's Norditropin, Upjohn, a division of Pfizer's Genotropin, etc.)
Basically, Iran, being subject to international embargo, has reduced standards for pharmacopeia than the international norm but a strong interest in manufacturing medications for its domestic market that its populace can use to treat medical conditions; as well as a strong interest in smuggling out manufactured goods that fetch a hefty price on the international black market to support its regime. Caveat emptor.